CMTMEDIUM SIGNALFINANCIAL10-K

CMT's operating cash flow declined meaningfully while capital expenditures increased substantially, indicating compressed cash generation amid elevated investment spending.

The company is experiencing margin pressure with gross profit and operating income both declining, while simultaneously ramping capital investments to nearly $17.3 million. This combination suggests CMT is in an investment phase that is temporarily pressuring profitability and cash generation, requiring careful monitoring of return on invested capital.

Comparing 2026-03-10 vs 2025-03-11View on EDGAR →
FINANCIAL ANALYSIS

CMT's financial performance weakened across key profitability metrics, with gross profit, operating income, and net income all declining year-over-year. The company substantially increased capital expenditures while operating cash flow fell significantly, creating a cash flow squeeze. Despite reduced debt levels, the combination of lower earnings and higher investment spending signals a transitional period that warrants investor attention.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
+49.8%
$11.5M$17.3M

Capital expenditure jumped 49.8% — major investment cycle underway; assess returns on deployment.

Operating Cash Flow
Cash Flow
-45.4%
$35.2M$19.2M

Operating cash flow fell 45.4% — earnings quality concerns; investigate working capital changes and non-cash items.

R&D Expense
P&L
-26.3%
$1.9M$1.4M

R&D spending cut 26.3% — could signal cost discipline or concerning reduction in innovation investment.

Net Income
P&L
-15.8%
$13.3M$11.2M

Net income declined 15.8% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-14.8%
$16.7M$14.2M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

Total Liabilities
Balance Sheet
+12.5%
$62.2M$70.0M

Liabilities increased 12.5% — monitor debt-to-equity ratio and interest coverage.

Gross Profit
P&L
-10.7%
$53.3M$47.6M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Total Debt
Balance Sheet
-10.5%
$19.7M$17.6M

Debt reduced 10.5% — deleveraging strengthens balance sheet and reduces financial risk.

LANGUAGE CHANGES
NEW — 2026-03-10
PRIOR — 2025-03-11
ADDED
As of March 9, 2026, the latest practicable date, 8,833,231 shares of the registrant s common stock were issued, which includes 338,554 shares of unvested restricted common stock.
Management's Discussion and Analysis of Financial Condition and Results of Operations 23 Item 7A.
As of December 31, 2025, the Company owned 82 molding presses including 18 in its Columbus, Ohio facility; 25 in its Matamoros, Mexico facility; 18 in its Cobourg, Canada facility; 10 in its Gaffney, South Carolina facility; 5 in its Winona, Minnesota facility; and 6 in its Monterrey, Mexico facility.
CAPITAL EXPENDITURES AND RESEARCH AND DEVELOPMENT Capital expenditures totaled approximately $17.3 million, $11.5 million, and $9.1 million in 2025, 2024, and 2023, respectively.
Management has estimated that costs related to research and development were approximately $1.4 million, $1.9 million and $1.7 million in 2025, 2024, and 2023, respectively.
+7 more — sign up free →
REMOVED
As of March 11, 2025, the latest practicable date, 8,895,735 shares of the registrant s common stock were issued, which includes 281,340 shares of unvested restricted common stock.
Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 7A.
As of December 31, 2024, the Company owned 82 molding presses including 19 in its Columbus, Ohio facility; 24 in its Matamoros, Mexico facility; 18 in its Cobourg, Canada facility; 10 in its Gaffney, South Carolina facility; 5 in its Winona, Minnesota facility; and 6 in its Escobedo, Mexico facility.
CAPITAL EXPENDITURES AND RESEARCH AND DEVELOPMENT Capital expenditures totaled approximately $11.5 million, $9.1 million, and $16.6 million in 2024, 2023, and 2022 respectively.
Management has estimated that costs related to research and development were approximately $1.9 million, $1.7 million and $1.6 million in 2024, 2023, and 2022, respectively.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →